✦ LIBER ✦

Oral Tolerance with Copolymer 1 for the Treatment of Multiple Sclerosis

✍ Scribed by Howard L. Weiner

Book ID: 123641893
Publisher: National Academy of Sciences
Year: 1999
Tongue: English
Weight: 928 KB
Volume: 96
Category: Article
ISSN: 0027-8424
DOI: 10.2307/47638

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral treatment for multiple sclerosis

✍ Joep Killestein; Richard A Rudick; Chris H Polman 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 106 KB

Development of oral cladribine for the t

Development of oral cladribine for the treatment of multiple sclerosis

✍ Hans-Peter Hartung; Orhan Aktas; Bernd Kieseier; Giancarlo Comi 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 268 KB

Treatment of multiple sclerosis and othe

Treatment of multiple sclerosis and other autoimmune diseases by oral tolerance to autoantigens

✍ Howard L. Weiner; Marika J. Hohol; Hikoaki Fukaura; Sally Kent; John Orav; Samia 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Oral laquinimod for treatment of relapsi

Oral laquinimod for treatment of relapsing-remitting multiple sclerosis

✍ Howard L Weiner 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 68 KB

Oral fingolimod for the treatment of pat

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis

✍ B. Singer; A. P. Ross; K. Tobias 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Experimental therapy of relapsing–remitt

Experimental therapy of relapsing–remitting multiple sclerosis with copolymer-1

✍ Dr Kenneth P. Johnson 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

After steroid therapy was shown to have some effect on multiple sclerosis (MS) in the early 1970s, the next drug that began to excite interest was copolymer-1 (COP-l), a treatment that was shown to inhibit experimental allergic encephalomyelitis (EM) in several mammalian species. We are now coming t